---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016391"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:22:38.193589+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma Q1 revenue $5.3M (+144% YoY); net loss narrows to $2.7M

## Summary
- Revenue $5.3M, up 144% YoY and 52% QoQ; record sales of ALKINDI SPRINKLE and Carglumic Acid.
- Net loss $2.7M ($0.10/share) vs $5.3M loss ($0.21) in Q1 2022; cash $14.7M.
- Launched Betaine Anhydrous; acquired rare disease candidate ET-600 (NDA filing expected 2024).
- G&A expenses $5.3M (incl $0.9M non-cash) from sales force expansion; R&D $0.5M vs $1.6M.
- CEO expects profitability in near future; ninth straight quarter of sequential revenue growth.

## SEC filing metadata
- accession: 0001493152-23-016391
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000149315223016391/0001493152-23-016391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000149315223016391/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016391
- JSON: https://secwatch.observer/filing/0001493152-23-016391.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016391.txt

## Key facts
- Earnings Releases
  Eton Pharmaceuticals, Inc. reported Q1 2023 results: revenue $5.3 million, net income -$2.7 million, EPS -$0.10.
  - Period: Q1 2023
  - Revenue: $5.3 million
  - Net income: -$2.7 million
  - EPS: -$0.10
  - Result: reported results
  source text: Net Revenue: Net revenues for the first quarter of 2023 were $5.3 million compared with $2.2 million in the prior year period. In both periods, revenue was comprised entirely of product sales and royalties, and the increase was driven primarily by growth in ALKINDI SPRINKLE and Carglumic Acid. Gross Profit : Gross profit for the first quarter of 2023 was $3.3 million compared with $1.3 million in the prior year period. Research and Development (R&D) Expenses : R&D expenses for the first quarter of 2023 were $0.5 million compared to $1.6 million in the prior year period. The decrease in R&D expenses was due primarily to a $0.5 million one-time development milestone payment made in the first quarter of 2022. General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2023 were $5.3 million compared to $4.8 million in the prior year period. The increase in G&A expenses was due primarily to incremental employee-related expenses associated with our sales force expansion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000149315223016391/0001493152-23-016391-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.